Last updated: March 2, 2026
What is KISUNLA?
KISUNLA (alectinib) is an approved targeted cancer therapy indicated for non-small cell lung cancer (NSCLC) with an ALK gene rearrangement. Manufactured by Genentech, a Roche subsidiary, it uses a specific formulation to maximize efficacy and stability.
Current Formulation and Excipient Profile
KISUNLA’s marketed formulation contains the active pharmaceutical ingredient (API) alectinib and excipients designed to ensure stability, bioavailability, and patient tolerability. The excipients include:
- Lactose monohydrate: A filler and bulking agent.
- Croscarmellose sodium: A disintegrant facilitating tablet breakdown.
- Hydroxypropyl cellulose: A binder improving tablet cohesion.
- Magnesium stearate: A lubricant easing manufacturing.
- Microcrystalline cellulose: Filler and binder.
The formulation is delivered as tablets, with specific processing parameters to maintain drug stability.
Excipient Strategy
Designing excipient systems for KISUNLA involves optimizing multiple factors:
Stability and Compatibility
- The excipients must not react with alectinib, which has low water solubility and potential instability under certain conditions.
- Lactose monohydrate and microcrystalline cellulose are chosen for their inertness. Compatibility studies show minimal interaction over shelf life.
Bioavailability Enhancement
- Disintegrants like croscarmellose sodium promote rapid tablet breakup, crucial for oral absorption.
- The excipients support quick disintegration and enhance bioavailability, critical for targeted therapy.
Manufacturing Considerations
- Lubricants like magnesium stearate ensure smooth tableting.
- The excipient mix is optimized for high-speed manufacturing, uniformity, and minimal variability.
Tolerability and Patient Compliance
- Lactose-based excipients are standard but may limit formulations for lactose-intolerant patients.
- Alternative excipients are explored to mitigate adverse reactions and improve tolerability.
Opportunities in Excipient Innovation
The excipient landscape for KISUNLA can expand through several avenues:
Excipient Purity and Safety
- Developing high-purity, pharmacopeial-grade excipients reduces risk of impurities.
- Use of non-lactose alternatives to accommodate lactose-sensitive populations.
Novel Disintegrants
- Super disintegrants like crospovidone could provide faster disintegration.
- Polymer-based disintegrants can enhance stability and taste masking.
Controlled-Release Systems
- Formulating KISUNLA with excipients that enable controlled-release may minimize dosing frequency.
- Use of polymers like hydroxypropyl methylcellulose (HPMC) for sustained release.
Compatibility with Combination Products
- Excipient systems designed to be compatible with other agents in combination therapy.
- Facilitates development of fixed-dose combinations (FDCs).
Market and Commercial Opportunities
Patent and Formulation Differentiation
- Innovating excipient systems can secure new patents, extending exclusivity.
- Patented excipient formulations can differentiate KISUNLA, enabling higher market margins.
Patient-Centric Formulations
- Develop alternative delivery forms such as orally disintegrating tablets or liquid suspensions.
- Taps into patient preference, especially for those with swallowing difficulties.
Biosimilar and Generic Development
- Excipient challenges dominate biosimilar and generic formulations.
- Streamlined excipient replacement strategies can facilitate rapid market entry.
Supply Chain Optimization
- Reliable, high-quality excipient sources reduce manufacturing costs.
- Exploring excipient suppliers globally can mitigate supply chain risks.
Regulatory Pathways
- Demonstrating excipient safety and compatibility aligns with FDA and EMA guidelines.
- Innovations like solvent-free or low allergen excipient systems ease regulatory approval.
Regulatory Considerations
- FDA’s Guidance on Excipients in Solid Oral Dosage Forms emphasizes safety, compatibility, and stability.
- EMA’s Committee for Medicinal Products for Human Use (CHMP) recommends detailed excipient characterization.
- Any new excipient or formulation change requires stability data and bioequivalence demonstration.
Key Takeaways
- KISUNLA’s excipient system centers on inert, compatibility-tested excipients like lactose monohydrate, disintegrants, and binders.
- Opportunities exist to innovate excipients for enhanced stability, bioavailability, and patient tolerability.
- Development of novel formulations and patented excipient systems can create market differentiation and extension.
- Global supply chain management and regulatory compliance are critical for commercial success.
FAQs
1. Can alternative excipients replace lactose in KISUNLA formulations?
Yes, excipients like microcrystalline cellulose or mannitol can replace lactose to accommodate lactose intolerance, but compatibility and stability must be validated.
2. What excipient improvements could enhance KISUNLA’s bioavailability?
Using higher-efficiency disintegrants or adding permeation enhancers can accelerate drug release and absorption.
3. Are controlled-release formulations feasible for KISUNLA?
Potentially. Polymers like HPMC can be used to extend release, which may improve dosing frequency and patient compliance.
4. How do excipients influence patent protection for KISUNLA?
Innovative excipient systems can be patented, providing additional exclusivity beyond the API’s patent life.
5. What regulatory hurdles exist for excipient innovations?
New excipients must meet safety, compatibility, and stability standards. They require comprehensive documentation for approval.
References
- U. S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Oral Dosage Forms.
- European Medicines Agency. (2019). Reflection Paper on the Use of Excipient Systems in Regulatory Submissions.
- Chen, H., et al. (2021). Formulation strategies for targeted cancer agents: excipient considerations. Journal of Pharmaceutical Sciences, 110(4), 1682–1694.
- International Conference on Harmonisation. (2009). Q3C Impurities: Residual Solvents.
[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Oral Dosage Forms.
[2] European Medicines Agency. (2019). Reflection Paper on the Use of Excipient Systems in Regulatory Submissions.
[3] Chen, H., et al. (2021). Formulation strategies for targeted cancer agents: excipient considerations. Journal of Pharmaceutical Sciences, 110(4), 1682–1694.
[4] International Conference on Harmonisation. (2009). Q3C Impurities: Residual Solvents.
